We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Collaborative Aims To Advance Novel Glioma Therapeutic

Collaborative Aims To Advance Novel Glioma Therapeutic content piece image

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Collaborative Aims To Advance Novel Glioma Therapeutic"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

PhoreMost, a UK-based biopharmaceutical company which aims to drug ‘undruggable’ disease targets, and Sentinel Oncology, have announced an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Polo-like kinase 1 (PLK1) inhibitor through preclinical development and IND enabling studies for the treatment of glioma.

Mitotic PLKs are widely recognized as playing crucial roles in disease-causing pathways, including K-Ras mutant cancers. Traditional approaches to drugging PLK enzymes have focused on targeting their active site; however, this tactic has been hindered by toxicity-associated adverse events. Sentinel Oncology’s allosteric PLK1 inhibitor takes the novel approach of targeting the Polo-box domain (PBD) of the PLKs, thereby aiming to mitigate adverse events seen by active site inhibitors.

Robert Boyle, CEO of Sentinel Oncology, commented: “We are very excited about the prospects for this program, and to be collaborating with PhoreMost to advance our allosteric PLK1 inhibitor. The program adds to our NeuroOncology pipeline, has started formal preclinical studies and is well-positioned to enter clinical development as a glioma treatment by 2021.”